Rosalind Franklin University
Rosalind Franklin University (RFU) is dedicated to advancing healthcare education and research through interprofessionalism and innovative practices. Named after Dr. Rosalind Franklin, the university fosters a collaborative environment for students and faculty to improve health outcomes and community wellness.
Rosalind Franklin University
3333 Green Bay Road, North Chicago, IL 60064
Patents
Combination serotonin specific reuptake inhibitor and serotonin 1A receptor partial agonist for reducing L-DOPA-induced dyskinesia
2025-04-29 • US-12285426-B2
View DetailsDurability test system for repetitive loading of a prosthetic socket
2025-04-22 • US-12279979-B2
View DetailsAntisense compounds targeting genes associated with cystic fibrosis
2024-07-23 • US-12042508-B2
View DetailsCCN3 and CCN3 peptides and analogs thereof for therapeutic use
2024-07-02 • US-12024544-B2
View DetailsChromenopyridine-based compounds and methods of making and use thereof
2023-11-14 • US-11814392-B2
View DetailsMethods of treating HIV-associated neurological disorders (HAND)
2023-10-17 • US-11786507-B2
View DetailsGliflozins and a method for their delivery during resuscitation from cardiac arrest to improve survival outcomes
2023-10-17 • US-11786540-B2
View DetailsCompounds and methods for the modulation of amyloid-β precursor protein
2023-08-22 • US-11732260-B2
View DetailsSystem and method for determining a discrimination index for fear-potentiated startle
2023-01-24 • US-11559231-B2
View DetailsCCN3 and CCN3 peptides and analogs thereof for therapeutic use
2022-11-22 • US-11505582-B2
View DetailsAntisense compounds targeting genes associated with cystic fibrosis
2021-09-14 • US-11116785-B2
View DetailsAntisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease
2020-09-29 • US-10787669-B2
View DetailsAntisense compounds targeting genes associated with cystic fibrosis
2020-01-28 • US-10544417-B2
View DetailsAntisense compounds targeting genes associated with cystic fibrosis
2020-01-07 • US-10525076-B2
View DetailsAntisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
2019-08-06 • US-10370667-B2
View DetailsCCN3 and CCN3 peptides and analogs thereof for therapeutic use
2019-07-16 • US-10351608-B2
View DetailsMethod and kit for treating a solid tumor and associated desmoplasia
2018-07-24 • US-10028906-B2
View DetailsCompounds for stabilizing ryanodine receptors from aberrant levels of calcium release
2018-07-03 • US-10011578-B2
View DetailsMethods and kits for diagnosing, prognosing and monitoring parkinson's disease
2018-05-15 • US-9970056-B2
View DetailsAntisense compounds targeting genes associated with cystic fibrosis
2017-12-12 • US-9840709-B2
View DetailsWhat We Do
A pro bono clinic providing healthcare services to the uninsured, staffed by students from various health programs.
A mobile health service that provides primary care, vaccinations, podiatry, physical therapy, medication reconciliation, and behavioral health counseling to vulnerable populations.
A four-year program that prepares students for a career in medicine with a focus on patient-centered care and interprofessional collaboration.
Advanced nursing programs that prepare students for leadership roles in healthcare.
A comprehensive pharmacy program that emphasizes interprofessional education and hands-on experience in various healthcare settings.
Psychological and Cognitive Health and Performance
Show More (1)Application Area
Show More (8)Diagnostics
Show More (3)Medical Devices
Battlefield Resuscitation
Show More (1)Key People
Erin Howe
Cancer Biologist
News & Updates
All Day
December 17, 2024 — 4:30 pm - 6:30 pm
RFU has launched a campaign to help raise donations for free healthcare services in the local community, running until December 16, 2024.
U.P. Oncolytics, a company in Rosalind Franklin University’s Helix 51 biomedical incubator, has been awarded Orphan Drug designation by the FDA for its oncolytic virus-based therapy to treat malignant glioma.
RFU has launched a campaign to help raise donations for free healthcare services in the local community.
Dr. Erin Howe has been awarded a $100,000 grant from the Mary Kay Ash Foundation to study the immune recognition of brain cancer metastases.